On December 21, 2017, parties in the lawsuits against Eli Lilly alleging heart attacks and strokes from testosterone products informed Illinois Federal MDL judge, Matthew F. Kennelly, that they had reached a global settlement in all cases filed against the pharmaceutical company in the multidistrict litigation over testosterone replacement therapy products. The deal comes just before...
Another Jury Finds AbbVie Misrepresented Risks of AndroGel & Awards $140 Million Verdict in Testosterone Heart Attack Lawsuit
On October 5, 2017, a Chicago jury ordered AbbVie, Inc. to pay more than $140 million to a Tennessee man, Jeffrey Konrad, who alleged that the Company misrepresented the risks of his testosterone replacement drug, AndroGel prescribed for Low-T, causing him to suffer a heart attack. This case is one of many in the testosterone...
$150 Million Punitive Damages Verdict in Testosterone Heart Attack Lawsuit for False Marketing
On July 24, 2017, a Chicago jury found in favor of claimant Jesse Mitchell in the second, much-anticipated AndroGel bellwether trial that started on July 5 in the testosterone replacement therapy (TRT) multidistrict litigation in the U.S. District Court for the Northern District of Illinois (Jesse Mitchell, et al. v. AbbVie, Inc., No. 14-9178, N.D....
Testosterone Heart Attack/Stroke Lawsuit Update – Trial Underway
Recently, the second, much-anticipated AndroGel bellwether trial started on July 5 in the testosterone replacement therapy (TRT) multidistrict litigation in the U.S. District Court for the Northern District of Illinois (Jesse Mitchell, et al. v. AbbVie, Inc., No. 14-9178, N.D. Ill.). This claim is one of thousands filed by men who suffered serious side effects...